Dr. Chun-hui Li’s Commentary on a Randomized Controlled Trial of Oral Fosfomycin for Down-Step Therapy in ESBL-E Complicated Urinary Tract Infections
Carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) have been designated as "urgent priorities" in antibiotic research and development by the WHO. Besides accelerating the development of new drugs, emphasizing the "repurposing" of existing drugs under antimicrobial stewardship (AMS) can help alleviate the threat of resistant bacteria. At the 2023 IDWeek congress, There is a study using oral fosfomycin as a step-down therapy for ESBL-E complicated urinary tract infections (cUTI), as an alternative to intravenous beta-lactam/beta-lactamase inhibitor (BL/BLIS) therapy, achieving non-inferiority results. Dr. Chun-hui Li from Xiangya Hospital, Central South University, introduces and comments on the study as follows.